AEGiS-CATIE: INFECTION FIGHTERS: Oral cidofovir?

INFECTION FIGHTERS: Oral cidofovir?

TreatmentUpdate 69, Volume 8, No 5; July 1996
Sean Hosein

Experiments are underway with the new anti-CMV drug cidofovir (VistideTM) to find out the best dose and schedule for treating and suppressing CMV infection. As that drug has to be given intravenously or by direct injection into the eye, researchers are testing oral cidofovir. At doses of 10 mg/kg of body weight, less than 5% of cidofovir was absorbed. It is not clear if this is will be useful as treatment or prevention of CMV disease. In the case of oral ganciclovir, only 2% to 5% is absorbed, but that is enough to benefit to people with CD4+ cell counts below 50. Perhaps further reports on oral cidofovir will emerge at the International AIDS Conference in Vancouver in July.

REFERENCES:

1. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with Human Immunodeficiency Virus: a phase I/II study. Journal of Infectious Diseases 1995;171:1431-1437.

2. Wachsman M, Petty BG, Cundy KC, et al. Pharmacokinetics, safety and bioavailablity of HPMPC (cidofovir) in Human Immunodeficiency Virus-infected subjects. Antiviral Research 1996;29(2,3):153-161.

960701
CATE6907

Always watch for outdated information. This article first appeard in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1996 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1996. AEGIS.